Fabry disease (α-galactosidase A deficiency)

Active Ingredient: Migalastat

Indication for Migalastat

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Migalastat is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.

For this indication, competent medicine agencies globally authorize below treatments:

123 mg once every other day

Route of admnistration

Oral

Defined daily dose

123 - 123 mg

Dosage regimen

From 123 To 123 mg once every 2 day(s)

Detailed description

The recommended dosage regimen in adults and adolescents 16 years and older is 123 mg migalastat once every other day at the same time of day.

Missed dose

Migalastat should not be taken on 2 consecutive days. If a dose is missed entirely for the day, the patient should take the missed dose of migalastat only if it is within 12 hours of the normal time the dose is taken. If more than 12 hours has passed the patient should resume taking migalastat at the next planned dosing day and time according to the every other day dosing schedule.

Dosage considerations

Migalastat exposure is decreased by approximately 40% when taken with food and therefore food should not be consumed at least 2 hours before and 2 hours after taking migalastat to give a minimum 4 hours fast. Clear liquids, including carbonated drinks, can be consumed during this period. Migalastat should be taken every other day at the same time of day to ensure optimal benefits to the patient.

Active ingredient

Migalastat

Migalastat is a pharmacological chaperone that is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of α-Gal A, the genotypes of which are referred to as amenable mutations. Migalastat binding stabilizes these mutant forms of α-Gal A in the endoplasmic reticulum and facilitates their proper trafficking to lysosomes.

Read more about Migalastat

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.